March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR Status
August 16th 2022Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.
Potential Biomarkers Identified in Post-Hoc Analysis of Apalutamide Plus ADT in mCRPC
June 7th 2022A post-hoc analysis of the phase 3 TITAN trial revealed potential biomarkers that may predict overall survival in patients with metastatic castration-resistant prostate cancer receiving apalutamide plus androgen deprivation therapy.
177Lu-PSMA-617 Has Similar Survival, But Increased PROs Vs Cabazitaxel in mCRPC
June 5th 2022Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.
Addition of Darolutamide to ADT and Docetaxel Did not Worsen Safety in mHSPC
May 31st 2022Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.